CRIS Current Research Information System

SCOTLANDI, KATIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.213
AS - Asia 3.591
EU - Europa 3.184
AF - Africa 266
SA - Sud America 203
OC - Oceania 6
Totale 11.463
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.153
SG - Singapore 1.019
VN - Vietnam 982
CN - Cina 882
IT - Italia 809
GB - Regno Unito 601
DE - Germania 505
SE - Svezia 323
HK - Hong Kong 317
IN - India 166
RU - Federazione Russa 156
BR - Brasile 147
NL - Olanda 136
CI - Costa d'Avorio 125
IE - Irlanda 122
FR - Francia 121
CH - Svizzera 106
KR - Corea 91
UA - Ucraina 84
TG - Togo 55
ZA - Sudafrica 50
EE - Estonia 46
FI - Finlandia 42
BG - Bulgaria 40
CA - Canada 37
JP - Giappone 35
AR - Argentina 29
JO - Giordania 29
ID - Indonesia 28
PL - Polonia 22
BE - Belgio 21
SC - Seychelles 15
MX - Messico 13
AT - Austria 12
TR - Turchia 12
ES - Italia 10
NG - Nigeria 9
CL - Cile 7
AU - Australia 6
LT - Lituania 6
EC - Ecuador 5
MA - Marocco 5
PE - Perù 5
PK - Pakistan 5
BD - Bangladesh 4
DO - Repubblica Dominicana 4
EG - Egitto 4
GR - Grecia 4
IR - Iran 4
VE - Venezuela 4
DK - Danimarca 3
HN - Honduras 3
HR - Croazia 3
IQ - Iraq 3
RO - Romania 3
CO - Colombia 2
KG - Kirghizistan 2
KH - Cambogia 2
ME - Montenegro 2
PY - Paraguay 2
TH - Thailandia 2
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CG - Congo 1
CR - Costa Rica 1
GT - Guatemala 1
HU - Ungheria 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MK - Macedonia 1
MY - Malesia 1
PT - Portogallo 1
QA - Qatar 1
SD - Sudan 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
UZ - Uzbekistan 1
YE - Yemen 1
Totale 11.463
Salva come PNG Salva come JPEG
Città #
Singapore 688
Southend 511
Ashburn 469
Fairfield 441
Chandler 387
Hong Kong 316
Woodbridge 223
Dong Ket 210
Hefei 210
Wilmington 206
Ann Arbor 195
Seattle 188
Ho Chi Minh City 186
Houston 185
Bologna 184
Santa Clara 162
Cambridge 157
Hanoi 156
Princeton 136
Abidjan 125
Beijing 125
Frankfurt am Main 124
Dublin 122
Bern 100
Boardman 100
Seoul 87
Dallas 62
Los Angeles 61
Nanjing 57
Lomé 55
Westminster 49
Jacksonville 46
Berlin 45
New York 45
Turin 43
Bremen 42
Padova 42
Sofia 40
Milan 37
Florence 35
Tokyo 34
Helsinki 31
Saint Petersburg 31
San Diego 31
Redondo Beach 30
Amman 29
Buffalo 27
Jinan 27
Falkenstein 23
London 23
Redmond 22
Biên Hòa 21
Jakarta 21
Nuremberg 21
Bengaluru 20
Phoenix 20
Shanghai 20
São Paulo 20
Guangzhou 19
Brussels 18
Shenyang 18
Catanzaro 17
Des Moines 17
Hebei 17
Amsterdam 16
Da Nang 16
Changsha 15
Haiphong 15
Rome 15
Falls Church 14
Tianjin 14
Warsaw 14
Can Tho 13
Ha Long 13
Mülheim 13
Dearborn 12
Medford 12
Munich 12
Nanchang 12
Redwood City 12
Jiaxing 11
Ninh Bình 11
Verona 11
Brooklyn 10
Chicago 10
Parma 10
Crocetta 9
Düsseldorf 9
Fuzhou 9
Lappeenranta 9
Wuhan 9
Bühl 8
Bắc Ninh 8
Hangzhou 8
Kuban 8
Ottawa 8
Paris 8
San Francisco 8
San Giovanni in Persiceto 8
Toronto 8
Totale 7.607
Salva come PNG Salva come JPEG
Nome #
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity 343
Altered modulation of lamin A/C-HDAC2 interaction and p21 expression during oxidative stress response in HGPS 306
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 278
Lamin A and prelamin A counteract invasiveness of osteosarcoma cells 238
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma 226
Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. 204
CD99 Acts as an Oncosuppressor in Osteosarcoma. 201
CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. 195
CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscape 195
CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression 192
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 190
Cell growth inhibition and apoptotic effect of the rexinoid 6-OH-11-O-hydroxyphenantrene on human osteosarcoma and mesenchymal stem cells. 186
New Insights into the Hepcidin-Ferroportin Axis and Iron Homeostasis in iPSC-Derived Cardiomyocytes from Friedreich's Ataxia Patient 184
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma 181
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. 174
Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). 173
Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma 170
Characterization of human mesenchymal stem cells from Ewing sarcoma patients. Pathogenetic implications 169
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 168
Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells 166
An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. 166
Insulin-like growth factor 2 mRNA-binding protein 3 is a novel post-transcriptional regulator of Ewing sarcoma malignancy 166
Targeting CD99 compromises the oncogenic effects of the chimera EWS-FLI1 by inducing re-expression of zyxin and inhibition of Gli1 activity 165
CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2. 162
A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function 162
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity 161
Treatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: the experience of a single institution 160
Apoptotic genes as potential markers of metastatic phenotype in human osteosarcoma cell lines. 160
Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation 159
SELNET clinical practice guidelines for soft tissue sarcoma and GIST 159
IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience 157
Does MGMT (O6-methylguanine–DNA methyltransferase) have a role in metastatic Ewing sarcoma (ES) patients (pts) undergoing temozolomide (TMZ) and irinotecan (IRI)? 157
Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling 155
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 153
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. 151
Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients 151
Targeting ROCK2 rather than ROCK1 inhibits Ewing sarcoma malignancy 150
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 149
Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study 148
Prelamin A-mediated recruitment of SUN1 to the nuclear envelope directs nuclear positioning in human muscle. 147
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research 146
Abstract 3201: Insulin-like growth factor 2 (IGF-2) mRNA binding protein 3 predicts poor prognosis and promotes cell proliferation in Ewing sarcoma 145
Correction to: ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis 143
Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells. 141
Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma 141
Immune-infiltrate characterization in localized osteosarcoma patients treated within protocol ISG-OS1. 138
Lamin A acts a tumor suppressor in Ewing sarcoma promoting neural differentiation and reducing cell migration and invasion 137
ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis 135
Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression 134
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 134
NVE-BEZ235 as a new therapeutic option for sarcomas. 133
Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Modulates Aggressiveness of Ewing Sarcoma by Regulating the CD164-CXCR4 Axis 131
Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma 128
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. 128
Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma 128
Prelamin A is involved in early steps of muscle differentiation. 126
Irinotecan and temozolomide upfront and in relapsed Ewing sarcoma: A translational study on MGMT (O6-methylguanine–DNA methyltransferase) and ABCG2 (MGMTLiberati) 125
Insulin-like growth factor binding protein 3 as an anti-cancer molecule in Ewing's sarcoma. 122
Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types 122
Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2) 117
Osteosarcoma and Ewing Sarcoma of Bone: An Italian Mono-Institutional Epidemiological Study 116
PD1 and PDL1 expression, tumoral microenvironment (TME) characterization and clinical implication in localized osteosarcoma 116
Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade 116
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma 115
Differentially expressed genes in multidrug resistant variants of U-2 OS human osteosarcoma cells. 113
miRNA signature predicts survival of Ewing’s sarcoma patients and miR34a directly influences cell chemosensitivity and malignancy 109
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells 107
Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. 104
Polymorphic variants of IGF2BP3 and SENCR have an impact on predisposition and/or progression of Ewing sarcoma 103
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33 100
Gene amplification is associated with methotrexate resistance in human osteosarcoma cell lines 96
Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene 89
SELNET clinical practice guidelines for bone sarcoma 87
The role of zyxin as a mediator between CD99 and EWS-FLI1 86
Zyxin in Ewing sarcoma: a novel role as mediator between CD99 and EWS-FLI1 81
Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma. 73
null 70
Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma 53
Corrigendum to “SELNET clinical practice guidelines for bone sarcoma” Critical reviews in oncology/hematology, vol. 174 (2022), 1–10 (Critical Reviews in Oncology / Hematology (2022) 174, (S1040842822001093), (10.1016/j.critrevonc.2022.103685)) 52
null 3
Totale 11.720
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.969
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.969
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021803 0 0 0 0 0 43 8 72 102 58 48 472
2021/20221.429 93 42 85 82 115 71 47 103 66 151 313 261
2022/20231.827 151 216 91 254 110 124 74 96 302 58 186 165
2023/2024500 35 93 45 58 35 85 35 32 18 25 12 27
2024/20251.909 106 246 149 143 272 104 101 84 28 168 111 397
2025/20262.789 626 625 413 405 515 205 0 0 0 0 0 0
Totale 11.720